Polymedication-Check With Insight in Patients' Medication Organisation and Comprehension of Generics

Sponsor
University Hospital, Basel, Switzerland (Other)
Overall Status
Completed
CT.gov ID
NCT03321058
Collaborator
University of Basel (Other)
125
1
9.6
13.1

Study Details

Study Description

Brief Summary

Patients using multiple drugs including generics have found different solutions to manage their medication. During a Polymedication-Check (medication review type 2a service in community pharmacies) additional information about the organisation of patients' medication in daily life will be compiled in Swiss community pharmacies. Data will allow to better address patients' needs in their medication organisation and comprehension of generics.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Assessment

Study Design

Study Type:
Observational
Actual Enrollment :
125 participants
Observational Model:
Case-Only
Time Perspective:
Cross-Sectional
Official Title:
Polymedikations-Check Und Medikamenten-Organisation im Alltag
Actual Study Start Date :
Jan 6, 2017
Actual Primary Completion Date :
Oct 1, 2017
Actual Study Completion Date :
Oct 24, 2017

Outcome Measures

Primary Outcome Measures

  1. Insight in patients' organisation of polymedication [retrospective 3 months]

    Patients organise their multiple medications differently in daily life. The study will investigate the different organisation strategies to get a better understanding of patients' behaviour. The behaviour is assessed with a questionnaire containing 14 questions on the management of medication including single choice, multiple choice and free text questions. As example the number of patients already using a medication organisation system will be assessed, the number of patients using a weekly or daily pillbox will be assessed, and who is filling the medication organisation system.

  2. Insight in patients' comprehension of generics [retrospective 3 months]

    Patients have a different comprehension of generics including their advantages and disadvantages. The study will investigate patients' comprehension of generics to get a better understanding of patients' behaviour. The comprehension is assessed with a questionnaire containing 4 questions on the believes about generics including single choice, multiple choice and free text questions. As example the number of patients knowing that they use generics is assessed and the patient's personal opinion on advantages and disadvantages of generics is investigated.

Secondary Outcome Measures

  1. Number of patients using Multicompartment Compliance Aids. [retrospective 3 months]

    Assessment of proportion of patients already using Multicompartment Compliance Aids prior to interview.

  2. Number of substitutable medicines. [retrospective 3 months]

    Assessment of number of brand name medication which could be substituted by generic medication and willingness of pharmacists to recommend generic medicines.

  3. Swallowing difficulties [retrospective 3 months]

    Prevalence of present and/or past swallowing difficulties and coping strategies will be assessed. A specific question (from SWAMECO) on the experienced swallowing difficulties is asked and will be answered on a visual analog scale (0 to 100%). If swallowing-difficulties are present, 2 more questions are asked: Which medication is difficult to swallow and how medication is altered in order to be able to swallow them.

  4. Recommended use of Multicompartment Compliance Aids [retrospective 3 months]

    Number of recommended use of Multicompartment Compliance Aids by pharmacists.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • at least 4 medicines for at least 3 months

  • at least 1 generic drug

  • at least 1 medicine of ATC code cardiovascular system (C01-10)

Exclusion Criteria:
  • medication provided in Multicompartment Compliance Aid or similar device by specific service (pharmacy, elderly home, home care)

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Basel Basel Basel-Stadt Switzerland 4056

Sponsors and Collaborators

  • University Hospital, Basel, Switzerland
  • University of Basel

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Kurt Hersberger, Prof. Dr., University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier:
NCT03321058
Other Study ID Numbers:
  • PMC-Medication-Organisation
First Posted:
Oct 25, 2017
Last Update Posted:
Oct 25, 2017
Last Verified:
Oct 1, 2017
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Kurt Hersberger, Prof. Dr., University Hospital, Basel, Switzerland

Study Results

No Results Posted as of Oct 25, 2017